Get With The Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead.

11 Analyses both within and outside of the GWTG-HF program have highlighted that out-of-pocket cost, prior authorization requirements, and formulary access issues associated with SGLT2i and ARNI may be significant barriers to use, compared with therapies with generic pricing available. 12 , 13 Applying Clinical Trial Findings to Real-World Populations While clinical trials have demonstrated substantial benefits with evidence-based therapies for management of HF, it is critical to understand how these benefits apply to the general population.

also in 13,097 other papers